Covered recipient · General Payments record
BRADLEY R CORR
Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology
General Payments · PY2018–2024
$53,044.99
- Reported across 72 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,412.50 | 5 |
| Travel and Lodging | $818.74 | 4 |
| Food and Beverage | $498.97 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $4,551.60 | 4 |
| ABBVIE INC. | $2,299.38 | 3 |
| Acerta Pharma LLC | $1,781.49 | 2 |
| ImmunoGen, Inc. | $1,279.00 | 2 |
| Gilead Sciences, Inc. | $818.74 | 4 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $169.38 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103504284 | CMS |
| ABBVIE INC. | $2,100.00 | 07/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103133119 | CMS |
| ABBVIE INC. | $30.00 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103504286 | CMS |
| AstraZeneca Pharmaceuticals LP | $68.99 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105655492 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,712.50 | 02/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105813703 | CMS |
| Gilead Sciences, Inc. | $23.00 | 05/30/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133870138 | CMS |
| Gilead Sciences, Inc. | $32.68 | 06/30/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133870140 | CMS |
| Gilead Sciences, Inc. | $381.53 | 06/30/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133870142 | CMS |
| Gilead Sciences, Inc. | $381.53 | 06/30/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133870144 | CMS |
| GlaxoSmithKline, LLC. | $1,600.00 | 01/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1115981538 | CMS |
| GlaxoSmithKline, LLC. | $123.60 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116227172 | CMS |
| GlaxoSmithKline, LLC. | $28.00 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116250946 | CMS |
| GlaxoSmithKline, LLC. | $2,800.00 | 02/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1116502929 | CMS |
| ImmunoGen, Inc. | $1,200.00 | 01/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1099941451 | CMS |
| ImmunoGen, Inc. | $79.00 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1099941453 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.